The FDA has lifted its hold on a clinical trial for a genetically engineered treatment for sickle cell disease, and CRISPR Therapeutics and Vertex Pharmaceuticals say they plan to start testing the therapy in U.S. patients by the end of the year. Enrollment is already underway for a clinical trial in Europe.
In May, partners CRISPR Therapeutics (NASDAQ: CRSP) and Vertex (NASDAQ: VRTX) halted their U.S. plans to test their drug, CTX001, in sickle cell disease-a red blood cell disorder-as well as beta thalassemia, an inherited disorder that affects hemoglobin in the blood. At the time of the… Read more »
UNDERWRITERS AND PARTNERS